MasterThis paper examines how the RO value of R&D expenditure by financial market changes as time goes by. It examines the relations between the R&D capital and the firm value for 4 years from the time firm increase its R&D expenditure unexpectedly. The financial market is proved to evaluate the R&D capital unexpectedly increased with real option logic. The market valuation doesn’t consider only the market uncertainty and the technology uncertainty at the same time but it also takes account in the market uncertainty and the technology uncertainty in the future. These effects are only significant right after the R&D capital unexpectedly increased. And the period is shorter than 1 year. The result shows that the operational performance doesn’...
In this paper we develop a novel valuation model and methodology to value a pharmaceutical R&D proje...
The purpose of this paper is to rework the building blocks of real option applications and to introd...
This paper provides a real option methodology in order to value a pioneer’s R&D investment opportuni...
The aim of this study is to provide new theoretical insights and empirical evidence on the effect o...
The aim of this study is to provide new theoretical insights and empirical evidence on the effect of...
Absent empirical validation of real option pricing in R&D, we discuss the evolution of three cases i...
HCERES Rang AInternational audienceThis paper studies investment in intellectual capital and corresp...
We argue that the NPV evaluation model has gained an undeservedly poor treatment in recent articles ...
Discounted cash flow methods for making R&D investment decisions cannot properly capture the opt...
Absent empirical validation of real option pricing in R&D, we discuss the evolution of three cas...
This paper estimates the responsiveness of irreversible investment to uncertainty using financial da...
Abstract Increase in globalization, improvements of capital markets and easier access to financing i...
A correct assessment of the innovation activities is critical to firm performance. To this purpose, ...
This paper provides a real option methodology for evaluating R&D investment opportunities assumi...
MBA - WBSThe shareholder value contributed by new technology is uncertain, making it difficult to d...
In this paper we develop a novel valuation model and methodology to value a pharmaceutical R&D proje...
The purpose of this paper is to rework the building blocks of real option applications and to introd...
This paper provides a real option methodology in order to value a pioneer’s R&D investment opportuni...
The aim of this study is to provide new theoretical insights and empirical evidence on the effect o...
The aim of this study is to provide new theoretical insights and empirical evidence on the effect of...
Absent empirical validation of real option pricing in R&D, we discuss the evolution of three cases i...
HCERES Rang AInternational audienceThis paper studies investment in intellectual capital and corresp...
We argue that the NPV evaluation model has gained an undeservedly poor treatment in recent articles ...
Discounted cash flow methods for making R&D investment decisions cannot properly capture the opt...
Absent empirical validation of real option pricing in R&D, we discuss the evolution of three cas...
This paper estimates the responsiveness of irreversible investment to uncertainty using financial da...
Abstract Increase in globalization, improvements of capital markets and easier access to financing i...
A correct assessment of the innovation activities is critical to firm performance. To this purpose, ...
This paper provides a real option methodology for evaluating R&D investment opportunities assumi...
MBA - WBSThe shareholder value contributed by new technology is uncertain, making it difficult to d...
In this paper we develop a novel valuation model and methodology to value a pharmaceutical R&D proje...
The purpose of this paper is to rework the building blocks of real option applications and to introd...
This paper provides a real option methodology in order to value a pioneer’s R&D investment opportuni...